Female pattern hair loss or androgenetic alopecia is the most common type of hair loss affecting women with reduced hair density and can has a significant negative psychological impact due to the uncertain relationship between androgens and this entity. Currently, the only clinically validated medication for increasing hair density in women with FPHL is topical minoxidil solution with FDA-approved in 2% product form but also increase to 5% in several countries. They have a study comparing the efficacy of the two concentrations show a significant advantage of 5% topical minoxidil solution. The previous studies show that oral administration of Zinc compounds improved hair growth but they still have a few studies about the efficacy and side effects. The common form of Zinc that use for hair loss treatment is chelated Zinc. Consequently, the molecules are attached to the amino acid methionine which enhance more bioavailable and more readily absorbed than inorganic form. The aim of this study was to determine efficacy and adverse effect of 5%minoxidil solution combined with chelated Zinc in FPHL.
Citation: Thuangtong R, Suvanasuthi S, Keoprasom N, Manapajon A, Maneeprasopchoke P (2013) A Pilot Study of the Efficacy in Treatment of Female Pattern Hair Loss using 5% Minoxidil Solution Combined with Oral Chelated Zinc Supplement. Hair Ther Transplant 4:113. doi: 10.4172/2167-0951.1000113